Combined therapy with probiotic VSL#3 and Omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice

Yoldaş İlktaç, HavvanurKızıltan, GülLanpir, Aslı DevrimOzansoy, MehmetGünal, Mehmet YalçınÖzmen Togay, SineKeskin, İlknurÖzdemir, Ekrem M.Kılıç, Ulkan2022-09-122022-09-122022https://hdl.handle.net/20.500.12868/1557https://www.webofscience.com/wos/woscc/full-record/WOS:000713193000004We published the abovementioned article about probiotic mixture VSL#3 on October 6, 2021. Since the product was named VSL#3 in our purchasing process in early 2016, it is referred to as VSL#3 in our article. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome® in the United States and Vivomixx® in Europe. The authors would like to apologise for any inconvenience causedeninfo:eu-repo/semantics/openAccessCytokinesProbioticOmega-3 fatty acidInflammatory bowel diseasesColitisCombined therapy with probiotic VSL#3 and Omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in miceArticle10.3409/fb_70-1.057014343Q4